Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma

• Published in: Journal of translational medicine 2023-03, Vol.21 (1), p.198-198, Article 198
• Main Authors: Hou, Xiaoying, Du, Hongzhi, Deng, Yufei, Wang, Haiping, Liu, Jinmi, Qiao, Jialu, Liu, Wei, Shu, Xiji, Sun, Binlian, Liu, Yuchen
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics; Antineoplastic Agents, Alkylating - therapeutic use; Bacteria; Bioluminescence; Brain cancer; Brain Neoplasms - genetics; Brain tumors; Cancer therapies; Cell cycle; Cell Line, Tumor; Chemotherapy; Correlation analysis; Discriminant analysis; DNA methylation; Drug resistance; Drug Resistance, Neoplasm; Enzyme-linked immunosorbent assay; Fecal microbiome; Feces; Flow cytometry; Functional Metabolomics; Gastrointestinal Microbiome; Glioma; Glioma - pathology; Histopathology; Humans; Immunomodulation; Immunoregulation; Individualized efficacy; Intestinal microflora; Laboratory animals; Lymphocytes T; Macrophages; Metabolites; Metabolomics; Mice; Microbiota; Nervous system; Pharmacodynamics; RNA, Ribosomal, 16S - genetics; rRNA 16S; Software; Temozolomide; Temozolomide - pharmacology; Temozolomide - therapeutic use; Therapeutic targets; Tumor necrosis factor-TNF; Xenografts
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04042-5

Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ's application, there still lack of strategies to increase the chemotherapy sensitivity. Luci-GL261 glioma orthotopic xenograft model combined bioluminescence imaging was utilized to evaluate the anti-tumor effect of TMZ and differentiate TMZ sensitive (S)/non-sensitive (NS) individuals. Integrated microbiomics and metabolomics analysis was applied to disentangle the involvement of gut bacteria in TMZ sensitivity. Spearman's correlation analysis was applied to test the association between fecal bacteria levels and pharmacodynamics indices. Antibiotics treatment combined TMZ treatment was used to confirm the involvement of gut microbiota in TMZ response. Flow cytometry analysis, ELISA and histopathology were used to explore the potential role of immunoregulation in gut microbiota mediated TMZ response. Firstly, gut bacteria composition was significantly altered during glioma development and TMZ treatment. Meanwhile, in vivo anti-cancer evaluation suggested a remarkable difference in chemotherapy efficacy after TMZ administration. Moreover, 16s rRNA gene sequencing and non-targeted metabolomics analysis revealed distinct different gut microbiota and immune infiltrating state between TMZ sensitive and non-sensitive mice, while abundance of differential gut bacteria and related metabolites was significantly correlated with TMZ pharmacodynamics indices. Further verification suggested that gut microbiota deletion by antibiotics treatment could accelerate glioma development, attenuate TMZ efficacy and inhibit immune cells (macrophage and CD8α T cell) recruitment. The current study confirmed the involvement of gut microbiota in glioma development and individualized TMZ efficacy via immunomodulation, hence gut bacteria may serve as a predictive biomarker as well as a therapeutic target for clinical TMZ application.